Download PDF
Hamostaseologie 2013; 33(04): 259-268
DOI: 10.5482/HAMO-13-07-0034
Review
Schattauer GmbH

Atherothrombotic risk in obesity

Atherothrombotisches Risiko bei Adipositas
L. Badimon
1   Centro de Investigación Cardiovascular, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau and IIB-Santpau
2   Cátedra de Investigación Cardiovascular, (UAB-HSCSP-Fundación Jesús Serra), Barcelona
,
R. Hernández Vera
1   Centro de Investigación Cardiovascular, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau and IIB-Santpau
2   Cátedra de Investigación Cardiovascular, (UAB-HSCSP-Fundación Jesús Serra), Barcelona
,
G. Vilahur
1   Centro de Investigación Cardiovascular, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau and IIB-Santpau
2   Cátedra de Investigación Cardiovascular, (UAB-HSCSP-Fundación Jesús Serra), Barcelona
› Author AffiliationsThis work was supported by PNS2010–16549 (to LB) and PNS2012–40208 (to GV) from the Spanish Ministry of Science. We thank Fundacion Jesus Serra-Fundación Investigación Cardiovascular (FIC), Barcelona, for their continuous support. G.V. is recipient of a grant from the Spanish Ministry of Science and Innovation (RyC-2009–5495; MICINN).
Further Information

Publication History

received: 01 July 2013

accepted in revised form: 02 September 2013

Publication Date:
28 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

A link between obesity and coronary artery disease development has been repeatedly proposed, possibly in part due to the development of a proinflammatory and prothrombotic state in obese subjects. Adipocytes secrete numerous hormones and cytokines (adipokines) which influence gene expression and cell functions in endothelial cells, arterial smooth muscle cells, and monocytes/macrophages favouring the development of an atherosclerotic vulnerable plaque. Moreover, the release of such biologically active molecules also promotes endothelial function impairment, disturbs the haemostatic and fibrinolytic systems, and produces alterations in platelet function affecting the initiation, progression, and stabilization of thrombus formation upon atherosclerotic plaque rupture.

In this review we will discuss the patho-physiological mechanisms by which obesity contributes to increase atherothrombosis paying special attention to its effects over thrombosis.

Zusammenfassung

Wiederholt wurde ein Zusammenhang zwischen Adipositas und koronarer Herzkrankheit postuliert, der teilweise auf die Entwicklung proinflammatorischer und prothrombotischer Zustände bei adipösen Patienten zurückzuführen sein könnte. Adipozyten sezernieren zahlreiche Hormone und Zytokine (Adipokine), die die Genexpression und Zellfunktionen in Endothelzellen, glatten Muskelzellen der Arterien sowie Monozyten/Makrophagen beeinflussen, so dass die Entwicklung von instabiler atherosklerotischer Plaque begünstigt wird. Außerdem fördert die Freisetzung solcher biologisch aktiver Moleküle eine endotheliale Dysfunktion, sie beeinträchtigt hämostatische und fibrinolytische Systeme und führt zu Veränderungen der Thrombozytenfunktion mit Auswirkungen auf Einsetzen, Progression und Stabilisierung der Thrombusbildung nach atherosklerotischer Plaqueruptur.

In diesem Review werden pathophysiologischen Mechanismen diskutiert, durch die Adipositas zur Förderung von Atherothrombose beiträgt. Dabei finden Auswirkungen jenseits der Thrombose besondere Beachtung.

Keywords

Atherosclerosis - thrombosis - obesity

Schlüsselwörter

Atherosklerose - Thrombose - Fettleibigkeit
 

  • References

  • 1 World Health Organization. Obesity and overweight. 2011 www.who.int/mediacentre/fact sheets/fs311/en/index.html
    PubMedGoogle Scholar
  • 2 Kelly T, Yang W, Chen CS. et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008; 32: 1431-1437.
    CrossrefPubMedGoogle Scholar
  • 3 Fontaine KR, Redden DT, Wang C. et al. Years of life lost due to obesity. JAMA 2003; 289: 187-193.
    CrossrefPubMedGoogle Scholar
  • 4 Poirier P, Giles TD, Bray GA. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 2006; 113: 898-918.
    CrossrefPubMedGoogle Scholar
  • 5 Alberti KG, Eckel RH, Grundy SM. et al. Harmonizing the metabolic syndrome. Circulation 2009; 120: 1640-1645.
    CrossrefPubMedGoogle Scholar
  • 6 Mottillo S, Filion KB, Genest J. et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
    CrossrefPubMedGoogle Scholar
  • 7 Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin Pharmacother 2011; 12: 1887-1900.
    CrossrefPubMedGoogle Scholar
  • 8 Badimon L, Martinez-Gonzalez J, Llorente-Cortes V. et al. Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 2006; 06: 439-456.
    CrossrefPubMedGoogle Scholar
  • 9 Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl. 01) S34-S42.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
    CrossrefPubMedGoogle Scholar
  • 11 Ibanez B, Vilahur G, Badimon JJ. Plaque progression and regression in atherothrombosis. J Thromb Haemost 2007; 05 (Suppl. 01) 292-299.
    CrossrefPubMedGoogle Scholar
  • 12 Badimon L, Badimon JJ, Vilahur G. et al. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 2002; 32: 225-231.
    CrossrefPubMedGoogle Scholar
  • 13 Badimon L, Vilahur G. Coronary atherothrombotic disease: progress in antiplatelet therapy. Rev Esp Cardiol 2008; 61: 501-513.
    CrossrefPubMedGoogle Scholar
  • 14 Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-477.
    PubMedGoogle Scholar
  • 15 Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
    CrossrefPubMedGoogle Scholar
  • 16 Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276-2283.
    CrossrefPubMedGoogle Scholar
  • 17 Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost. 2013 110. doi:10.1160/TH13-03-0212.
    PubMedGoogle Scholar
  • 18 Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
    CrossrefPubMedGoogle Scholar
  • 19 De Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008; 54: 945-955.
    CrossrefPubMedGoogle Scholar
  • 20 Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008; 37: 635-646.
    CrossrefPubMedGoogle Scholar
  • 21 Pilz S, Marz W. Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med 2008; 46: 429-434.
    PubMedGoogle Scholar
  • 22 Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48: 1905-1914.
    PubMedGoogle Scholar
  • 23 Goralski KB, Sinal CJ. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can J Physiol Pharmacol 2007; 85: 113-132.
    CrossrefPubMedGoogle Scholar
  • 24 Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1-16.
    CrossrefPubMedGoogle Scholar
  • 25 Alessi MC, Lijnen HR, Bastelica D, Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 2004; 33: 290-297.
    PubMedGoogle Scholar
  • 26 Cusi K, Maezono K, Osman A. et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-320.
    CrossrefPubMedGoogle Scholar
  • 27 Kato H, Kashiwagi H, Shiraga M. et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224-230.
    CrossrefPubMedGoogle Scholar
  • 28 Mattu HS, Randeva HS. The role of adipokines in cardiovascular disease. J Endocrinol 2013; 216: T17-T36.
    CrossrefPubMedGoogle Scholar
  • 29 Enriori PJ, Evans AE, Sinnayah P, Cowley MA. Leptin resistance and obesity. Obesity (Silver Spring) 2006; 14 (Suppl. 05) 254S-8S.
    CrossrefPubMedGoogle Scholar
  • 30 Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
    CrossrefPubMedGoogle Scholar
  • 31 Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949.
    CrossrefPubMedGoogle Scholar
  • 32 Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008; 37: 753-768.
    CrossrefPubMedGoogle Scholar
  • 33 Chavey C, Mari B, Monthouel MN. et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003; 278: 11888-11896.
    CrossrefPubMedGoogle Scholar
  • 34 Maquoi E, Munaut C, Colige A. et al. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002; 51: 1093-1101.
    CrossrefPubMedGoogle Scholar
  • 35 Hopps E, Caimi G. Matrix metalloproteinases in metabolic syndrome. Eur J Intern Med 2012; 23: 99-104.
    CrossrefPubMedGoogle Scholar
  • 36 Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52: 410-428.
    CrossrefPubMedGoogle Scholar
  • 37 Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012; 56: 232-244.
    CrossrefPubMedGoogle Scholar
  • 38 Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005; 102: 15575-15580.
    CrossrefPubMedGoogle Scholar
  • 39 Laxton RC, Hu Y, Duchene J. et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res 2009; 105: 921-929.
    CrossrefPubMedGoogle Scholar
  • 40 Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 2002; 105: 2923-2928.
    CrossrefPubMedGoogle Scholar
  • 41 Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007; 06: 51-59.
    CrossrefPubMedGoogle Scholar
  • 42 Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
    CrossrefPubMedGoogle Scholar
  • 43 Wolk R, Berger P, Lennon RJ. et al. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003; 108: 2206-2211.
    CrossrefPubMedGoogle Scholar
  • 44 Michiels C. Endothelial cell functions. J Cell Physiol 2003; 196: 430-443.
    CrossrefPubMedGoogle Scholar
  • 45 Badimon L, Vilahur G, Padro T. Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol 2009; 62: 1161-1178.
    CrossrefPubMedGoogle Scholar
  • 46 Steinberg HO, Chaker H, Leaming R. et al. Obesity/ insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
    PubMedGoogle Scholar
  • 47 Tounian P, Aggoun Y, Dubern B. et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 358: 1400-1404.
    CrossrefPubMedGoogle Scholar
  • 48 Benjamin EJ, Larson MG, Keyes MJ. et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109: 613-619.
    CrossrefPubMedGoogle Scholar
  • 49 Pulerwitz T, Grahame-Clarke C, Rodriguez CJ. et al. Association of increased body mass index and impaired endothelial function among Hispanic women. Am J Cardiol 2006; 97: 68-70.
    CrossrefPubMedGoogle Scholar
  • 50 Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011; 15: 1911-1926.
    CrossrefPubMedGoogle Scholar
  • 51 Van de Werf F, Ardissino D, Betriu A. et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28-66.
    PubMedGoogle Scholar
  • 52 Hamdy O, Ledbury S, Mullooly C. et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119-2125.
    CrossrefPubMedGoogle Scholar
  • 53 Sciacqua A, Candigliota M, Ceravolo R. et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 2003; 26: 1673-1678.
    CrossrefPubMedGoogle Scholar
  • 54 Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009; 19: 440-449.
    CrossrefPubMedGoogle Scholar
  • 55 Targher G, Zoppini G, Moghetti P, Day CP. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 2010; 36: 41-48.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Basili S, Pacini G, Guagnano MT. et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538.
    CrossrefPubMedGoogle Scholar
  • 57 Davi G, Guagnano MT, Ciabattoni G. et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014.
    CrossrefPubMedGoogle Scholar
  • 58 Anfossi G, Russo I, Trovati M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr Diabetes Rev 2006; 02: 409-430.
    CrossrefPubMedGoogle Scholar
  • 59 Anfossi G, Mularoni EM, Burzacca S. et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998; 21: 121-126.
    CrossrefPubMedGoogle Scholar
  • 60 Anfossi G, Russo I, Massucco P. et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004; 34: 482-489.
    CrossrefPubMedGoogle Scholar
  • 61 Russo I, Traversa M, Bonomo K. et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity (Silver Spring) 2010; 18: 788-797.
    CrossrefPubMedGoogle Scholar
  • 62 De Pergola G, Pannacciulli N, Coviello M. et al. sPselectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors. Nutr Metab Cardiovasc Dis 2008; 18: 227-232.
    CrossrefPubMedGoogle Scholar
  • 63 Angelico F, Alessandri C, Ferro D. et al. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-1174.
    CrossrefPubMedGoogle Scholar
  • 64 Natal C, Restituto P, Inigo C. et al. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab 2008; 93: 2319-2327.
    CrossrefPubMedGoogle Scholar
  • 65 Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59: 981-982.
    CrossrefPubMedGoogle Scholar
  • 66 Greisenegger S, Endler G, Hsieh K. et al. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. Stroke 2004; 35: 1688-1691.
    CrossrefPubMedGoogle Scholar
  • 67 Bavbek N, Kargili A, Kaftan O. et al. Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy?. Clin Appl Thromb Hemost 2007; 13: 391-397.
    CrossrefPubMedGoogle Scholar
  • 68 Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des 2011; 17: 47-58.
    CrossrefPubMedGoogle Scholar
  • 69 Ishibashi T, Kimura H, Uchida T. et al. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1989; 86: 5953-5957.
    CrossrefPubMedGoogle Scholar
  • 70 Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339-3347.
    CrossrefPubMedGoogle Scholar
  • 71 Van der Loo B, Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler Thromb Vasc Biol 1999; 19: 672-679.
    CrossrefPubMedGoogle Scholar
  • 72 Hernández RVera, Vilahur G, Ferrer-Lorente R. et al. Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 2141-2148.
    CrossrefPubMedGoogle Scholar
  • 73 Hernández RVera, Vilahur G, Badimon L. Obesity with insulin resistance increase thrombosis in wild-type and bone marrow-transplanted Zucker fatty rats. Thromb Haemost 2013; 109: 319-327.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Visser M, Bouter LM, McQuillan GM. et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-2135.
    CrossrefPubMedGoogle Scholar
  • 75 Molins B, Pena E, de la RTorre, Badimon L. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res 2011; 92: 328-337.
    CrossrefPubMedGoogle Scholar
  • 76 Molins B, Pena E, Vilahur G. et al. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-2246.
    CrossrefPubMedGoogle Scholar
  • 77 Corsonello A, Perticone F, Malara A. et al. Leptindependent platelet aggregation in healthy, over-weight and obese subjects. Int J Obes Relat Metab Disord 2003; 27: 566-573.
    CrossrefPubMedGoogle Scholar
  • 78 Murakami T, Horigome H, Tanaka K. et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 2007; 119: 45-53.
    CrossrefPubMedGoogle Scholar
  • 79 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
    CrossrefPubMedGoogle Scholar
  • 80 Meade TW, Ruddock V, Stirling Y. et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
    CrossrefPubMedGoogle Scholar
  • 81 Samad F, Pandey M, de Waard V, Loskutoff D. Elevated PAI-1 and tissue factor gene expression in obese mice: a possible mechanism for the increased risk for cardiovascular disease associated with obesity. Fibrinol Proteol 1997; 11: 17.
    PubMedGoogle Scholar
  • 82 Kopp CW, Kopp HP, Steiner S. et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003; 11: 950-956.
    CrossrefPubMedGoogle Scholar
  • 83 Napoleone EADIS, Amore C. et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk?. J Thromb Haemost 2007; 05: 1462-1468.
    CrossrefPubMedGoogle Scholar
  • 84 Folsom AR, Conlan MG, Davis CE, Wu KK. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol 1992; 02: 481-494.
    PubMedGoogle Scholar
  • 85 Nagai N, Hoylaerts MF, Cleuren AC. et al. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb Res 2008; 122: 549-555.
    CrossrefPubMedGoogle Scholar
  • 86 Fontana L, Eagon JC, Trujillo ME. et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-1013.
    CrossrefPubMedGoogle Scholar
  • 87 Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009; 10: 554-563.
    CrossrefPubMedGoogle Scholar
  • 88 Lijnen H, Collen D. Molecular and cellular basis of fibrinolysis. In: Hoffman RBE, Shattil SJ, Furie B. et al. (eds). Elsevier: Philadelphia; 2005
    Google Scholar
  • 89 Rissanen P, Vahtera E, Krusius T. et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001; 25: 212-218.
    CrossrefPubMedGoogle Scholar
  • 90 Janand-Delenne B, Chagnaud C, Raccah D. et al. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-317.
    CrossrefPubMedGoogle Scholar
  • 91 Koistinen HA, Dusserre E, Ebeling P. et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects. Diabetes Metab Res Rev 2000; 16: 364-369.
    CrossrefPubMedGoogle Scholar
  • 92 Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-1687.
    CrossrefPubMedGoogle Scholar
  • 93 Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000; 49: 666-671.
    CrossrefPubMedGoogle Scholar
  • 94 Rega G, Kaun C, Weiss TW. et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005; 111: 1938-1945.
    CrossrefPubMedGoogle Scholar
  • 95 Mavri A, Alessi MC, Bastelica D. et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001; 44: 2025-2031.
    CrossrefPubMedGoogle Scholar
  • 96 Estelles A, Dalmau J, Falco C. et al. Plasma PAI-1 levels in obese children effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86: 647-652.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 97 Sudi KM, Gallistl S, Trobinger M. et al. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents. J Pediatr Endocrinol Metab 2001; 14: 85-94.
    PubMedGoogle Scholar
  • 98 Aubert H, Frere C, Aillaud MF. et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 01: 791-797.
    CrossrefPubMedGoogle Scholar
  • 99 Hori Y, Gabazza EC, Yano Y. et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665.
    CrossrefPubMedGoogle Scholar
  • 100 Ageno W, Becattini C, Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
    CrossrefPubMedGoogle Scholar
  • 101 Di Minno G, Mannucci PM, Tufano A. et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost 2005; 03: 1459-1466.
    CrossrefPubMedGoogle Scholar
  • 102 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
    CrossrefPubMedGoogle Scholar
  • 103 Allman-Farinelli MA, Chey T, Bauman AE. et al. Age, period and birth cohort effects on prevalence of overweight and obesity in Australian adults from 1990 to 2000. Eur J Clin Nutr 2008; 62: 898-907.
    CrossrefPubMedGoogle Scholar
  • 104 Eichinger S, Hron G, Bialonczyk C. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683.
    CrossrefPubMedGoogle Scholar
  • 105 Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 37: 903-907.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 106 Steffen LM, Cushman M, Peacock JM. et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost 2009; 07: 746-751.
    CrossrefPubMedGoogle Scholar
  • 107 Aguilera CM, Ramirez-Tortosa MC, Mesa MD, Gil A. Protective effect of monounsaturated and polyunsaturated fatty acids on the development of cardiovascular disease. Nutr Hosp 2001; 16: 78-91.
    PubMedGoogle Scholar